Effect of naloxone on pituitary hypersecretory syndromes.
D000172:Acromegaly / Q000188:drug therapy*; D000224:Addison Disease / Q000188:drug therapy*; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D004054:Diethylstilbestrol / Q000378:metabolism; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D009347:Nelson Syndrome / Q000188:drug therapy*; D010908:Pituitary Hormones, Anterior / Q000097:blood*; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D008083:beta-Lipotropin / Q000097:blood
D010908:Pituitary Hormones, Anterior; D009270:Naloxone; D004054:Diethylstilbestrol; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013006:Growth Hormone; D008083:beta-Lipotropin; D006854:Hydrocortisone